drugset
drugset / Trial / NCT06165237

A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"

NCT06165237 ↗

Phase 1 Completed 30 enrolled Boryung Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this clinical trial is to evaluate the drug-drug interaction and safety between "BR6001-1" and "BR6001-2" in healthy adult volunteers

Timeline

Start
2023-03-30
Primary completion
2023-05-09
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BR6001-1 Unknown — —
Subject BR6001-2 Unknown — —

Indications

peptic ulcer disease